Efficacy of osimertinib in a patient with non-small cell lung cancer harboring epithelial growth factor receptor exon 19 deletion/T790M mutation, with poor performance status

Osimertinib, a third-generation epithelial growth factor receptor (EGFR) tyrosine kinase inhibitor, has been demonstrated to be effective for treating patients with T790M-positive advanced non-small cell lung cancer (NSCLC) with a relatively good performance status (grade 0–1). Reports of therapeuti...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Mol Clin Oncol
Egile Nagusiak: Nishii, Yoichi, Hataji, Osamu, Ito, Kentaro, Watanabe, Fumiaki, Kobayashi, Tetsu, D’Alessandro-Gabazza, Corina, Toda, Masaaki, Taguchi, Osamu, Yamamoto, Nobuyuki, Gabazza, Esteban C.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: D.A. Spandidos 2018
Gaiak:
Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5774518/
https://ncbi.nlm.nih.gov/pubmed/29399354
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2017.1522
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak